Company Development Timeline

History: Targeted Medical Pharma Development Timeline

1996 Laboratory Industry Services LLC is founded as a Nevada limited liability
1998 Investigations into Gulf War Syndrome yield promising data regarding neurotransmitter depletion and disease.
1998 Targeted Medical Foods was established. Sentra AM and Sentra PM were developed and groundwork for Targeted Cellular Technology began.
2002 Targeted Medical Foods becomes a Limited Liability Corporation as Targeted Medical Pharma Inc.
2003 Targeted Medical Foods is established as a subsidiary of the company and primary Medical Food distributor.
2003 Physician Therapeutics enters into licensing agreement for the sales and marketing rights for six products with J Network, in Japan.
2003 Physician Therapeutics enters into licensing agreement with Pliva Krakow Pharmaceutical Company for European distribution.
2004 American Journal of Medicine publishes data and findings from the Gulf War Syndrome study. New York Times editorializes findings.
2006 Physician Therapeutics introduces first Convenience Packs for sale and distribution.
2008 First double-blind placebo controlled studies completed for Medical Foods and generic drugs.
2009 Four Medical Food patents are issued by the United States Patent and Trademark Office and assigned to Targeted Medical Pharma Inc.
2009 Double-blind clinical study completed for Theramine and naproxen.
2009 One Medical Food Patent is issued by the United States Patent and Trademark Office and assigned to Targeted Medical Pharma Inc.
2010 Double-blind placebo controlled study completed for Theramine and Ibuprofen.
2012 Theramine and naproxen double-blind clinical study published in the American Journal of Therapeutics.
2012 Company commences public trading of securities on the OTCBB under the symbol TRGM.
2012 Sentra PM and trazodone double-blind clinical study published in the Journal of Central Nervous System Disease.
2012 Two decades of research into Gulf War Illness by company founders culminate with confirmation of disordered parasympathetic activity.
2013 Comprehensive pharmaceutical billing patent issued by the United States Patent and Trademark Office and assigned to Targeted Medical Pharma.
2013 Initial data on the company’s erythrocyte stimulating system (ESS) for the treatment of chronic anemia released.
2013 Reported results from an observational study of the dietary management of autistic spectrum disorders with medical foods.
2013 Launched AminoLabs, a division of the company that specializes in the development and commercialization of proprietary dietary supplements.
2013 Launched Clearwayz for sustained sinus and immune support, the first in a line of dietary supplements.
2014 Published in the American Journal of Therapeutics, a second double-blind clinical study examining the effects of Theramine on chronic back pain and inflammation.
2014 Published in The Journal of Central Nervous System Disease, an open label, pilot study examining the effects of Sentra AM and Sentra PM on PTSD.
2015 Company founder Dr. William E. Shell, steps down from his roles as CEO and Chairman and is replaced by Kim Giffoni.
2016 Chief Medical Officer, Dr. David Silver, develops Grotrexa and AppTrim Japan for exclusive distribution in Japan.
2016 Company partners with B-L-E-S-S, a Japanese organization committed to selling Grotrexa and AppTrim Japan
2016 Company partners with Healthy Focus Ltd. a Hong Kong Based company for the distribution of Theramine, Percura and Trepadone in Hong Kong and mainland China.
2016-2017 Company restructures management and company operations
2017 Company partners with New Zealand based Douglas Pharmaceuticals for the exclusive distribution of Clearwayz in New Zealand.
2017 Board of Directors appoints Chief Operating Officer, Marcus Charuvastra, as the Interim Managing Director.
2018 Company appoints Douglas Gintz as Chief Marketing and Technology Officer.
2018 Company partners with Ukranian based marketing and distribution company ZDRAVO, for the exclusive distribution of Theramine in the Ukraine.
2018 Company partners with Russian based pharmaceutical company, HELIX Pharma, for the exclusive distribution of Clearwayz in Russia.